Both PHF23 and TP53RK mRNA downregulation was confirmed by RNA-seq analysis in the blood of enitociclib-treated patients and further studies are warranted to uncover the utility of enitociclib to downregulate these potential cancer targets. Here, TP53RK is linked to cancer.